biostudies-literatureUnknown15(2)Thoueille PWorld Anti-Doping AgencySalmeterol is a commonly used β₂-agonist included on the List of Prohibited Substances and Methods published by the World Anti-Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α-hydroxysalmeterol, in plasma and urine after inhalation. The model was used to evaluate the ability of the current minimum reporting level (MRL) of 10 ng/mL for salmeterol to discriminate between permitted and prohibited use of salmeterol. Six studies on healthy participants, chronic asthmatics, or athletes were pooled and provided a total of 1175 concentrations (275 and 398 for salmeterol and 185 and 317 for α-hydroxysalmeterol in plasma and urine, respectively) from 92 individuals. A two-compartment model assuCPT: pharmacometrics & systems pharmacologye70187https://www.ebi.ac.uk/biostudies/studies/S-EPMC12823318biostudies-literaturePharmacometric-Based Evaluation of Salmeterol and Its Metabolite α-Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control.PMC12823318Mazzoni IDanion AGuidi MPetrou MDeventer KGirardin FRThoueille PBuclin TRabin OHostrup MfalsePharmacometric-Based Evaluation of Salmeterol and Its Metabolite α-Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control.Salmeterol is a commonly used β₂-agonist included on the List of Prohibited Substances and Methods published by the World Anti-Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α-hydroxysalmeterol, in plasma and urine after inhalation. The model was used to evaluate the ability of the current minimum reporting level (MRL) of 10 ng/mL for salmeterol to discriminate between permitted and prohibited use of salmeterol. Six studies on healthy participants, chronic asthmatics, or athletes were pooled and provided a total of 1175 concentrations (275 and 398 for salmeterol and 185 and 317 for α-hydroxysalmeterol in plasma and urine, respectively) from 92 individuals. A two-compartment model assu2026-01-01T00:00:00Z2026 Feb2026-06-06T19:27:58.004Z2026-06-04T03:10:29.787ZS-EPMC128233184154345110.1002/psp4.70187